Loading your page…
Frontiers in pediatrics
By Lu J, Deng J, Wang H and 4 others.
Despite high DTaP coverage, pertussis resurgence persists. Infants under 2 months of age face severe outcomes due to vaccine ineligibility and rising macrolide-resistant B. pertussis (MRBP), yet treatment options remain limited.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
To analyze epidemiology, clinical profiles, and antimicrobial management of hospitalized pertussis infants under 2 months of age, identifying risk factors for severity and evaluating real-world SMZ-TMP use.
Retrospective study of PCR/culture-confirmed pertussis infants hospitalized at Shenzhen Children's Hospital (2015-2024). Data included transmission sources, clinical severity, and antimicrobial regimens. Logistic regression analysis was performed to analyze the risk factors for severe pertussis, and a P-value < 0.05 was considered statistically significant. The predictive value for severe pertussis was evaluated using the receiver operating characteristic (ROC) curve.
Among 321 infants with a history of exposure, parents constituted the primary infection source (46.1%, 148/321). 25 infants with Bordetella pertussis infection (aged 24-59 days) received off-label SMZ-TMP without bilirubin encephalopathy or renal dysfunction. Leukocytosis, and an elevated neutrophil-lymphocyte ratio were predictors of severe disease. Exposure history, apnea, decreased oxygen saturation, tachypnea, tachycardia, elevated white blood cell count, and an increased neutrophil-to-lymphocyte ratio were identified as significant risk factors for severe pertussis.
In infants under 2 months of age with pertussis, parents are the primary source of infection. In infants under 2 months of age with macrolide-resistant pertussis, treatment with SMZ-TMP was effective and no severe adverse reactions were observed.
Published in Frontiers in pediatrics. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
